Abstract：【Objective】To detect the expression level and mutation of MUC16 in non-small cell lung cancer (NSCLC), and to explore the relationship of expression and mutation of MUC16 with prognosis. 【Methods】A total of 113 patients with NSCLC in our hospital were selected as the research objects. The cancer tissues were in the observation group (A group) and the adjacent "normal" tissues were selected as the control group (B group). Real-time quantitative PCR (qRT-PCR) was used to detect the level of MUC16 mRNA in lung adenocarcinoma and the expression level of MUC16 in lung adenocarcinoma was retrieved from the Ualcan database. The immunohistochemistry was applied to detect the expression level of MUC16 protein. The high throughput sequencing was performed to identify the mutation of MUC16 gene in NSCLC. The diagnostic value of MUC16 mRNA in NSCLC was analyzed and the relationship of prognosis with MUC16 expression level and mutation in patients with NSCLC cancer was analyzed as well. 【Results】In the Ualcan database, the level of MUC16 mRNA in lung adenocarcinoma tissue was shown higher than that in normal lung tissue (P<0.05). The level of MUC16 mRNA and protein positive rate in the A group were higher than those in the B group (P<0.05). The area under the curve (AUC) of MUC16 mRNA level in the diagnosis of NSCLC was 0.882, the cutoff value was 1.213, the specificity was 84.1%, and the sensitivity was 83.2%. The 5-year survival rate of MUC16 positive non-small cell lung cancer patients was 30.14%, which was lower than that of MUC16 negative patients (65.00%, P<0.05). The 5-year survival rate of 22.22% in patients with non MUC16 mutation was lower than that in patients with MUC16 mutation (55.88%, P<0.05). 【Conclusion】MUC16 plays an important role in the occurrence and development of NSCLC cancer, and it has certain diagnostic value. Its expression level and mutation are closely related to the prognosis of NSCLC, which may provide a new potential target for the treatment of NSCLC.
白山, 曹诚. 非小细胞肺癌组织中粘蛋白抗原16的表达水平和突变的意义[J]. 医学临床研究, 2022, 39(3): 382-385.
BAI Shan, CAO Cheng. Expression, Mutation and Clinical Significance of MUC16 in Non-small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 382-385.
[1] BAO S M,HU Q H,YANG W T,et al. Targeting epidermal growth factor receptor in non-small-cell-lung cancer: current state and future perspective[J].Anticancer Agents Med Chem,2019,19(8):984-991.
[2] 李妍,徐兴祥. 19del与L858R的晚期非小细胞肺癌TKI治疗疗效及预后差异的研究进展[J].中国医师杂志,2019,21(11):1758-1760.
[3] FAN K,WANG J,SUN W,et al. MUC16 C-terminal binding with ALDOC disrupts the ability of ALDOC to sense glucose and promotes gallbladder carcinoma growth[J].Exp Cell Res,2020,394(1):112-118.
[6] 王丽. 中国原发性肺癌诊疗规范(2015年版)解读[J].世界临床药物,2016,37(7):433-436.
[7] 史云舒,李盼华,李班班,等. EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价[J].中国肺癌杂志,2019,22(5):299-305.
[8] ZHANG Y X,WANG Y J,WANG J G. MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH[J].Exp Ther Med,2018,15(2):2203-2211.
[9] HU J,SUN J. MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment[J].Oncoimmunology,2018,7(10):1-18.
[10] KATOH M. Multilayered prevention and treatment of chronic inflammation,organ fibrosis and cancer associated with canonical WNT/βcatenin signaling activation (Review)[J].Int J Mol Med,2018,42(2):713-725.
[11] 宋毓平,张庆华,龚丹妮,等. MUC16突变在皮肤恶性黑色素瘤患者预后中的作用分析[J].重庆医学,2019,48(19):99-102.
[12] LAKSHMANAN I,SALFITY S,SESHACHARYULU P,et al. MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53[J].Clin Cancer Res,2017,23(14):3906-3917.
[13] 郭承涛,彭小波,湛先保. 胰腺黏液性囊腺癌基因突变的检测及其临床意义[J].中国肿瘤生物治疗杂志,2019,26(4):440-444.
2022, Vol. 39 
